Treosulfan in the treatment of advanced ovarian cancer

• Verfasst von: Chekerov, Radoslav [VerfasserIn]
• Verfasst von: Wischnik, Arthur [VerfasserIn]
• Titel: Treosulfan in the treatment of advanced ovarian cancer
• Titelzusatz: results of a German multicenter non-interventional study
• Verf.angabe: Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach and Jalid Sehouli
• E-Jahr: 2015
• Jahr: December 2015
• Umfang: 7 S.
• Fussnoten: Gesehen am 29.11.2018
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2015
• Band/Heft Quelle: 35(2015), 12, Seite 6869-6875
• ISSN Quelle: 1791-7530
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: elderly
• Sach-SW: non-interventional study
• Sach-SW: ovarian cancer
• Sach-SW: Treosulfan
• K10plus-PPN: 1584620013

Abstract

Background: Data on routine systemic treatment of patients with ovarian cancer are currently available only to a limited degree. The alkylating agent treosulfan is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of ovarian carcinoma. The present non-interventional study analyzed the clinical use of treosulfan in Germany, evaluating the mode of application, toxicity, and response and survival rate. Patients and Methods: Two hundred and forty-eight ovarian cancer patients in 57 Centers, who received treosulfan mainly either i.v. (5,000-8,000 mg/m2 d1, q21d or q28d) or p.o. (400-600 mg/m2 d1-14 or 21, q28d) for at least one therapy cycle were evaluable and were included in the study. Results: With a median age of 70 years (range=36-92 years), predominantly elderly patients received treosulfan treatment. Most participants presented serous histology (131, 52.8%) and advanced-stage FIGO III (122, 49%) or IV (55, 22%) disease. Median ECOG status was 1 (range=0-2), whereas cardiac co-morbidity was common (31%). Treosulfan was usually administered as second- (26%), third- (21%) or fourth-line (17%) therapy. Two hundred and one patients received i.v. and 47 p.o. treatment. The most common reason for dose modifications was due to hematological toxicity (46%). The main reason for a therapy discontinuation was progressive disease (38.5%). Response was observed in 25.8% of participants, disease stabilization in 28.6 % and progress in 45.6%. The median progression-free and overall survival was 196 and 405 days, respectively. Conclusion: In predominantly elderly and heavily pre-treated patients with recurrent ovarian cancer, treosulfan featured a clinical relevant efficacy and well-manageable, mostly hematological, toxicity, which resulted in a positive therapeutic index.